Less Bleeding with Rivaroxaban for Venous Thromboembolism (VTE)

J Thromb Haemost 2015 Sep; 13:1590
Two large industry-funded trials
n = 8000 with acute symptomatic DVT or PE receiving rivaroxaban vs LMWH/VKA
(previous published in NEJM 2010;363:2499 and NEJM 2012; 366:1287)
HR for major bleeding = 0.54 for rivaroxaban compared to LMWH/VKA
HR for severe clinical presentations = 0.35
HR for less-severe clinical course = 0.46
FFP, RBC transfusions and prothrombin complex concentrates used less often w rivaroxaban

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s